Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: Observational study of 30 cases in everyday practice

Joint Bone Spine

Volumn 77, Issue 2, 2010, Pages 142-145

  Toussirot, Éric ^a,f,g   Pertuiset, Édouard ^b   Sordet, Christelle ^c   Augé, Benoît ^a   Wendling, Daniel ^a,f   Pallot Pradès, Béatrice ^d   Collet, Philippe ^d   Lohse, Anne ^e   Balblanc, Jean Charles ^e  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b Pontoise Hospital   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^d Saint Etienne Hospital   (France)

^e Belfort Hospital   (France)

^f UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^g HÔPITAL SAINT JACQUES   (France)

Author keywords

Bacterial infections; Rituximab; Safety

Indexed keywords

GLUCOCORTICOID; IMMUNOGLOBULIN; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ARTICLE; BACTERIAL ARTHRITIS; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; CELLULITIS; DISEASE DURATION; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; ERYSIPELAS; FEMALE; FOLLOW UP; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LOWER RESPIRATORY TRACT INFECTION; LUNG ABSCESS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; OSTEITIS; PROSTHESIS INFECTION; PYELONEPHRITIS; RECURRENT INFECTION; RHEUMATOID ARTHRITIS; SEPTICEMIA; SKIN ABSCESS; SKIN INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BACTERIAL INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77949570681     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.01.008     Document Type: Article

References (19)

1. Toussirot E., Streit G., and Wendling D. Infectious complications with anti-TNFα therapy in rheumatic diseases. A review. Recent Pat Inflamm Allergy Drug Discov 1 (2007) 39-47
2. Furst D.E. The risk of infections with biologic therapy for rheumatoid arthritis. Semin Arthritis Rheum (2008) [Epub ahead of print]
3. Fleischmann R.M. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Semin Arthritis Rheum 38 (2009) 265-280
4. ®.
5. Pham T., Claudepierre P., Deprez X., et al. Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammation (CRI) section of the French Society of Rheumatology (Société française de rhumatologie, SFR). Joint Bone Spine 72 Suppl. 1 (2005) S1-58
6. Salliot C., Dougados M., and Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials. Ann Rheum Dis 68 (2009) 25-32
7. Doran M.F., Crowson C.S., Pond G.R., et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46 (2002) 2287-2293
8. Doran M.F., Crowson C.S., Pond G.R., et al. Predictors of infections in rheumatoid arthritis. Arthritis Rheum 46 (2002) 2294-2300
9. Askling J., Fored C.M., Brandt L., et al. Time-dependant increase in risk of hospitalization with infection among Swedish RA patients treated with TNFα antagonists. Ann Rheum Dis 66 (2007) 1339-1344
10. Dixon W.G., Watson K., Lunt M., et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54 (2006) 2368-2376
11. Edwards J.C., Szczepanski L., Szechinski J., et al. Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350 (2004) 2572-2581
12. Emery P., Fleischmann R., Filipowicz-Sosnowska A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment Results of a phase IIb randomized, double blind, placebo-controlled dose-ranging trial. Arthritis Rheum 54 (2006) 1390-1400
13. Cohen S.B., Emery P., Greenwald M.W., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54 (2006) 2793-2806
14. Keystone E., Fleischmann R., Emery P., et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis. An open label extension analysis. Arthritis Rheum 56 (2007) 3896-3908
15. Gottenberg J.E., Ravaud P., Bardin T., et al. Prospective follow-up of rituximab treatment in 965 patients with refractory rheumatoid arthritis (630 patients-year): tolerance and efficacy data from the French registry AIR (autoimmunity and rituximab). Arthritis Rheum 58 Suppl. (2008) S611 [abstract]
16. Van Vollenhoven R.F., Emery P., Bingham C.O., et al. Long-term safety of rituximab: 6-year follow-up of the rheumatoid arthritis (RA) clinical trials and re-treatment population. Arthritis Rheum 58 Suppl. (2008) S300 [abstract]
17. Genovese M.C., Emery P., Ruderman E., et al. Immunoglobulin levels and infection rates in patients with rheumatoid arthritis (RA) treated with repeated courses of rituximab. Arthritis Rheum 57 Suppl. (2007) S149-S150 [abstract]
18. ®.
19. Pham T., Fautrel B., Gottenberg J.E., et al. Rituximab (Mabthera) therapy and safety management: clinical tool and guide. Joint Bone Spine 75 Suppl. (2008) S1-S99